More weight-loss drugs offered in type 2 diabetes care shake-up

The treatment of millions of people with type 2 diabetes must be more personalized, with better access to new drugs, including weight loss drugs, the health care assessment body for England, Wales and Northern Ireland has recommended.

He calls the “greatest upheaval” movement in type 2 diabetes care in a decade.

Offering more people, new drugs will prevent complications such as heart disease, brain vascular accidents and renal lesions, will reduce NHS costs and potentially save lives, says the National Institute for Health and Care (NAY).

About 4.6 million people in the United Kingdom receive a diagnosis of diabetes – from these 90% have type 2, of which 1.3 million additional is likely to be unmatched.

Type 2 diabetes means that there is too much glucose or blood sugar. This makes vascular cerebral accidents, heart attacks, heart failure and other health conditions much more risk. It is now so common that 10% of the NHS budget will treat it.

Nice, which produces advice for the NHS on how to provide patients with the best care, recommends a distance from a “one size” approach and to a more personalized treatment.

He calls for more recent diabetes against diabetes called SGLT-2 inhibitors, who protect the heart and kidneys as well as the drop in blood sugar, to become the treatment of the first choice for all diabetic patients. About 2.3 million people will be eligible for these drugs.

Some 22,000 lives could be saved if 90% of all diabetic patients had been prescribed, known as Nice, but access is not equal through the United Kingdom. It is proven that women, the elderly and blacks are less likely to prescribe them.

“There is an emergency to find ways to increase the absorption of SGLT-2 inhibitors, because if we were to reach perfect adoption, the nation would be much healthier,” said Dr. Waqaar Shah, Chairman of the Committee of Directives.

Only one in five people with type 2 diabetes and cardiovascular disease is currently prescribed for drugs.

The prescription of the tablets to more people would particularly benefit those who live in poorer areas and ethnic minorities, known as Nice.

Under direction, which is still at a project stage and must undergo a consultation, around 750,000 people more with type 2 diabetes Will be offered GLP-1 agonists such as semaglutide and liraglutide, which have become very popular like the drugs contained in weight loss jabs.

Adults with cardiovascular disease and some who develop type 2 before the age of 40 are the recommended groups to offer them.

These drugs can be used both to reduce blood sugar and to support some people with weight loss.

Professor Jonathan BENGER, Deputy Managing Director and Chief doctor at Nice, said that the updated directives were “a significant development” in the treatment of type 2 diabetes which could help prevent heart attacks, strokes and other serious complications before they occur.

“These guidelines mean that more people will be offered drugs, where it is right to do so, to reduce their future risk of poor health,” he added.

Directives are part of a long -term NHS plan in England to reduce health inequalities and focus on prevention of poor health in the first place.

The charitable organization Diabetes UK said that the announcement has propelled the treatments for type 2 diabetes “in the 21st century”.

“These guidelines could greatly contribute to the relaxation of the burden of life with this incessant condition, as well as to help inequalities in the treatments and results of type 2 diabetes,” said Douglas Twenefour, head of the charity.